Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.

Breaking & Recent News Regenerx Biopharmaceuticals RGRX

Regenerx Biopharmaceuticals Inc is focused on the discovery and development of novel molecules to accelerate tissue and organ repair. Its operations are confined to one business segment: the development and marketing of product candidates based on Thymosin Beta 4 (Tß4), an amino acid peptide. The company has formulated Tß4 into three distinct product candidates in clinical development: RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease or other pathology; RGN-137, a topical gel for dermal wounds and reduction of scar tissue; and RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications that may be treated by systemic administration.


Recent & Breaking News (OTCQB:RGRX)

RegeneRx and Digital Aria Sign Product License and Stock Purchase Agreements

Business Wire March 7, 2014

RegeneRx Receives Israeli Patent for Treatment of Dry Eye Syndrome

Business Wire February 24, 2014

RegeneRx Receives Notice of Allowance from U.S. Patent Office for Treatment and Prevention of Neuro and Muscular Degenerative Diseases

Business Wire January 16, 2014

RegeneRx Receives Orphan Drug Designation for T?4 in the Treatment of Neurotrophic Keratopathy

Business Wire January 3, 2014

RegeneRx Receives Notice of Allowance from Canadian Patent Office for Reversal of Skin Aging

Business Wire December 20, 2013

RegeneRx Releases Results of Phase 2 Clinical Trial on Patients with Epidermolysis Bullosa

Business Wire June 24, 2013

RegeneRx Issues Letter to Sharholders

Business Wire May 13, 2013

RegeneRx Issues $225,000 Convertible Note

Business Wire April 1, 2013

RegeneRx Receives Notice of Allowance for 2nd U.S. Heart Patent

Business Wire March 8, 2013

RegeneRx Receives Notice of Allowance from Chinese Patent Office for Treatment and Prevention of Heart Disease

Business Wire February 7, 2013